View source for Sodium zirconium cyclosilicate

==Administration<ref>Packham, D. K., Rasmussen, H. S., Lavin, P. T., El-Shahawy, M. A., Roger, S. D., Block, G., … Singh, B. (2015). Sodium zirconium cyclosilicate in hyperkalemia. The New England Journal of Medicine, 372(3), 222–231.</ref>==
*Type: Potassium binder, [[antidote]]
*Dosage Forms: 5 g (1 ea, 30 ea); 10 g (1 ea, 30 ea), empty contents into glass with 45 mL of water
*Routes of Administration: Oral
*Common Trade Names: Lokelma

==Adult Dosing==
===Hyperkalemia===
10 g TID PO for up to 48 hours, then 10 g once daily

==Pediatric Dosing==

==Special Populations==
===[[Drug pregnancy categories|Pregnancy Rating]]===
*unlikely to affect fetus as not absorbed

===Lactation risk===
*unlikely to be in breast milk as not absorbed

===Renal Dosing===
None

===Hepatic Dosing===
None

==Contraindications==
*Allergy to class/drug
*Avoid in GI motility disorders

==Adverse Reactions==
===Serious===


===Common===
*Mild to moderate edema
*Hypokalemia

==Pharmacology==
*Metabolism: none
*Excretion: feces

==Mechanism of Action==
*Highly selective, oral potassium removing agent
*Non-absorbed zirconium silicate that captures potassium in exchange fro hydrogen and sodium
*Increases fecal potassium excretion through binding K+ in GI tract

==Comments==
*Onset of action at 1.0 hour and median time to achieving normal potassium levels at 2.2 hours, with 92% achieving normal potassium within 48 hours. 
*Not used as an emergency treatment for life threatening hyperkalemia due to delayed onset of action
*Available at Harbor-UCLA, but not yet widely available in the community
*If asked by nephrology to give Kayexalate, kindly suggest Lokelma instead

==See Also==
[[Hyperkalemia]]

==References==
<references/>

[[Category:Pharmacology]]
[[Category:FEN]]